S450
Clinical - Gynaecological
ESTRO 2026
Keywords: Cervical cancer, Quality of Life , sexual health
(Figure-2)
Digital Poster 2405 Failure Pattern and Survival Impact of Modern Radiotherapy for Locally Advanced Cervical Cancer: Real-World vs EMBRACE II in Single Institute Tissana Prasartseree 1,2 , Pittaya Dankulchai 1,3 , Akrapol Suppasedtanon 1 , Natthanicha Sauenram 1 , Naritsa Rotmuenwai 1 , Wiwatchai Sittiwong 1,3 , Pongpop Tuntapakul 1,3 , Wajana Thaweerat 1,3 , Pitchayut Wongsuwan 1,3 , Ratchapas Romrattaphan 1,3 , Nantakan Apiwarodom 1,3 , Yaowalak Chansilpa 1,3 1 Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 2 Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3 Siriraj Brachytherapy Center (SiBTC), Siriraj Center of Excellence (SiCOE), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Conclusion: In this series, CC treated with CRT/adjuvant- RT achieved excellent control rates low side- effects and and global QoL, but poor sexual health outcomes. References: 1. Kirchheiner K, et al. Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study. Gynecol Oncol. 2015 Mar;136(3):415- 23. 2. Shylasree TS, et al. Quality of life in long term survivors of cervical cancer: A cross sectional study. Indian J Cancer. 2021 Apr- Jun;58(2):171-178. 3. Ferguson SE, et al. Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial
Purpose/Objective: To compare clinical outcomes, failure
patterns, and prognostic impact on overall survival (OS) and survival after failure of a Real-World (RW) locally advanced cervical cancer cohort treated with IGABT-based CCRT against the EMBRACE II cohort in a single institute. Material/Methods: This retrospective cohort study included 188 LACC patients (FIGO 2018 IB3–IVA) from 2020-2022 treated with definitive CCRT (weekly cisplatin with 45-50Gy EBRT) and 3D- IGABT in Real-World cohort (RW,n=147) compared to the registered EMBRACE II cohort (n=41) at our institute. Statistical analyses included descriptive and Kaplan– Meier analyses. OS and overall survival after failure (OSAF) comparisons were made across four failure arms: No failure, LRF only,
Comparing Simple Versus Radical Hysterectomy. J Clin Oncol. 2025 Jan 10;43(2):167-179.
Made with FlippingBook - Share PDF online